Dr. Ratnakar Singh is currently a postdoctoral fellow in the Department of Comparative Biosciences at University of Illinois Urbana Champaign. Prior to this he was postdoctoral fellow in department of Thoracic Head & Neck Medical Oncology at MD Anderson Cancer Center, Houston, Texas, USA. Dr. Singh has about 10 years of experience in cancer research and is the author of more than 25 peer reviewed publications, patent and conference papers.
Dr. Singh completed his master degree in Medical Biochemistry in 2008 from Jawaharlal Institute of postgraduate and Medical research (JIPMER) Puducherry, India. He later completed his PhD in Biochemistry and Molecular Oncology in 2014 from All India Institute of Medical Sciences (AIIMS) New Delhi, India. After his PhD he worked as a research scientist in AIIMS and later came to the United States for his postdoctoral training in translational cancer research.
His main research interest is investigating the role of Cell cycle kinases as viable therapeutic targets for lung and head & Neck cancer. His work at MD Anderson has led to the establishment of a Plk1 inhibitor as an effective therapy for Non-Small Cell Lung Cancer (NSCLC) which has supported the translation of the drug to clinical trials for NSCLC patients.
He received Award of Excellence in 2012 from Carcinogenesis Foundation for his work on DPPIII regulation in glioblastoma in New Delhi, India. In the same year he also received Nature Publishing Group Award for best poster 2012 in ‘Cell Death’ Gordon Research Conference, in Italy for his work on entitled ‘Synergistic role of PTEN and p53 in conferring taxol sensitivity to human glioblastoma cells’. Dr. Singh has reviewed several scientific articles, reviews, and book chapters. He has recently awarded “The Jeffrey Lee Cousin Fellowship 2018” for outstanding contribution to lung cancer research.
Dr. Singh’s long-term goal is to make significant contributions in the field of precision medicine and develop new therapeutic targets and biomarkers that predict the best anticancer treatment for an individual patient.
Biochemistry and Cell Biology Cancer biology Cancer Cell Biology Cancer Cell Signaling and Cancer Cell Metabolism cell cycle checkpoint Cell cycle regulation cell signaling DNA Damage Repair DNA damage response DNA methylation DNA repair DNA repication, DNA repair, DNA polymerases Drug Resistance Epigenetics Genomics Glioblastoma Gliomas histopathology HNSCC Immuno-oncology Immunotherapy Lung cancer Metabolomics Molecular Biology molecular biology of gliomas molecular genetics Molecular Oncology Molecular Targets NSCLC, esophageal carcinoma, gastric cancer Oncology Oncology and Carcinogenesis Oxidative Stress Patient-derived Xenografts plk1 proteomics Proteomics Signal Transduction Targeted Therapy
Editorial Board Memberships
Ratnakar is not currently contributing as an editor for any journal or publisher.
Showing 6 of 34
Pre Publication Reviews
Your statistics are calculated based on the information you have submitted to Publons.
Read more about them here.
Compare your statistics to those of any research field on Publons using the form below. Leaving the form blank will compare your statistics to all research fields on Publons.
Reviews (last 12 months)
Reviews (average per year)
Review to Publication ratio
Journal Impact Factors of journals reviewed for
The distribution of the Journal Impact Factors of journals Ratnakar Singh has reviewed for.
All fields reviewers
Total reviews over time
A cumulative record of Ratnakar Singh's total number of reviews.
Reviews per month
The total number of reviews performed by Ratnakar Singh each month.
Average review length
The average number of words per review (for which we have content), compared to the average of All fields reviewers and the average of reviewers at affiliated institutions.
Weekly review punchcard
The distribution of days that reviews were performed on, compared to All fields reviewers and reviewers at affiliated institutions.